Tiagabine , 98% , 115103-54-3
CAS NO.：115103-54-3
Empirical Formula: C20H25NO2S2
Molecular Weight: 375.55
MDL number: MFCD00865317
| Pack Size | Price | Stock | Quantity |
| 10mg | RMB553.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 192oC dec. |
| Boiling point: | 568.0±50.0 °C(Predicted) |
| Density | 1.208±0.06 g/cm3(Predicted) |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
| pka | 3.86±0.20(Predicted) |
| Water Solubility | ≥ 13.5mg/mL in Water |
Description and Uses
Gabitril was launched in Denmark for use as an add-on therapy in patients refractory to other epilepsy therapies. The compound can be synthesized in five steps beginning with a bis-thiophenyl ketone derivative to produce the (R)-(-)- enantiomer. Its anti-epileptic activity resides in its potent and selective inhibition of GABA synaptosomal uptake. Tiagabine is selective for the GAT-1 GABA transporter in neurons and glia thus enhancing inhibitory GABAergic transmission. Because it has practically no effect on other uptake or receptor systems, it has a reduced potential for neurological side-effects. In particular, it does not have the benzodiazepine-like sedative effects. It is able to cross the blood brain barrier and is considered the most potent GABA uptake inhibitor known.
A GABA uptake inhibitor
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-37/39 |
